Episode Details
Back to Episodes
Dasher Neuroscience's Phase 2 Enrollment Complete: AI-driven CNS drug ahead to readout — promise tempered by typical small‑cap biotech risks
Published 3 weeks, 1 day ago
Description
Dasher Neuroscience (TPEx: 7829) announced completion of patient enrollment in its global Phase 2 trial of YA-101 for Multiple System Atrophy (MSA). The milestone validates an operational execution step for an AI‑discovered CNS candidate but leaves efficacy, safety and commercial pathway unresolved until readouts and regulatory interactions.